Lupeol

产品说明书

Print
Chemical Structure| 545-47-1 同义名 : Monogynol B; Fagarasterol; β-Viscol; NSC 90487; Lupenol; Clerodol
CAS号 : 545-47-1
货号 : A813209
分子式 : C30H50O
纯度 : 97%
分子量 : 426.72
MDL号 : MFCD00017351
存储条件:

Pure form Sealed in dry, 2-8°C

In solvent -20°C:3-6个月-80°C:12个月

溶解度 : -
动物实验配方:
生物活性
描述 Lupeol is a pentacyclic triterpene found in various species in the plant kingdom with anti-inflammatory, antioxidant, anti-diabetic, and anti-mutagenic effects. In vitro, lupeol at 10 µg/mL and 20 µg/mL, significantly inhibited keratinocyte proliferation by 53% and 64%, respectively, after 24 h treatment. Additionally, in keratinocytes, lupeol treatment resulted in the activation of Akt, p38, and Tie-2[4]. In vivo, lupeol decrease serum prostate-specific antigen levels and inhibit the tumorigenicity of prostate cancer (CaP) cells[5].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.34mL

0.47mL

0.23mL

11.72mL

2.34mL

1.17mL

23.43mL

4.69mL

2.34mL

参考文献

[1]Zhang L, Tu Y, et al. A novel mechanism of hepatocellular carcinoma cell apoptosis induced by lupeol via Brain-Derived Neurotrophic Factor Inhibition and Glycogen Synthase Kinase 3 beta reactivation. Eur J Pharmacol. 2015 Sep 5;762:55-62.

[2]Jin Y, Lyu Y, et al. Lupeol enhances radiosensitivity of human hepatocellular carcinoma cell line SMMC-7721 in vitro and in vivo. Int J Radiat Biol. 2015 Feb;91(2):202-8.

[3]Saleem M. Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett. 2009;285(2):109-115.

[4]Pereira Beserra F, Xue M, Maia GLA, Leite Rozza A, Helena Pellizzon C, Jackson CJ. Lupeol, a Pentacyclic Triterpene, Promotes Migration, Wound Closure, and Contractile Effect In Vitro: Possible Involvement of PI3K/Akt and p38/ERK/MAPK Pathways. Molecules. 2018 Oct 30;23(11):2819. doi: 10.3390/molecules23112819. PMID: 30380745; PMCID: PMC6278408.

[5]Saleem M, Murtaza I, Tarapore RS, Suh Y, Adhami VM, Johnson JJ, Siddiqui IA, Khan N, Asim M, Hafeez BB, Shekhani MT, Li B, Mukhtar H. Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling. Carcinogenesis. 2009 May;30(5):808-17. doi: 10.1093/carcin/bgp044. Epub 2009 Feb 20. PMID: 19233958; PMCID: PMC2722146.